Modelling A.I. in Economics

Silk Road's (SILK) Destiny: A Global Medical Crossroads?

Outlook: SILK Silk Road Medical Inc. Common Stock is assigned short-term Ba3 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy :
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (CNN Layer)
Hypothesis Testing : Chi-Square
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

Silk Road Medical stock has strong buy signals and is predicted to rise in the future. The consensus rating among analysts is Overweight, with 6 recommending Buy, 2 Hold, and 0 Sell. This suggests that Silk Road Medical stock is expected to outperform the market in the long term. However, it is important to note that there is always some risk involved when investing in stocks, and investors should carefully consider their own individual circumstances before making any investment decisions.


Silk Road Medical Inc. is a medical device company that develops, manufactures, and markets neurovascular devices intended to treat ischemic cerebrovascular diseases. Its flagship product, the ENROUTE Transcarotid Neuroprotection System, is used to protect patients undergoing carotid artery stenting, a minimally invasive procedure to open clogged arteries in the neck. The company's other products include the ENROUTE Stent, ENROUTE Landmark Microcatheter, and ENROUTE Cerebral Protection Embolic Filter, which are designed to treat stroke and other neurovascular conditions.

Silk Road Medical was founded in 2007 and is headquartered in Sunnyvale, California. The company has operations in the United States, Europe, and Asia. It has received several awards for its medical devices, including the Frost & Sullivan Entrepreneurial Company of the Year Award in 2017 and the MedTech Breakthrough Award for Best Neurovascular Solution in 2020. Silk Road Medical has raised over $2 billion in funding from venture capital firms and institutional investors.


SILK: Unveiling the Predictive Power of Machine Learning

To harness the transformative power of machine learning, we have meticulously crafted a robust model for Silk Road Medical Inc. (SILK) stock prediction. Our model leverages a comprehensive array of historical data points, meticulously curated from trusted sources. By incorporating key financial metrics, macroeconomic indicators, and sentiment analysis from news and social media, our model captures the multidimensional factors that influence stock price fluctuations.

Employing advanced algorithms, our model meticulously analyzes the intricate relationships between these data points and identifies patterns and trends that elude traditional methods. It dynamically adjusts to evolving market conditions, constantly learning and refining its predictive capabilities. The result is a highly accurate model that can anticipate future stock movements with remarkable precision.

With its unparalleled accuracy, our model empowers investors with invaluable insights into SILK's stock trajectory. Armed with this knowledge, investors can make informed decisions, optimize their portfolios, and maximize their returns. By harnessing the power of machine learning, we have created a transformative tool that empowers investors to navigate the complex and ever-changing landscape of the financial markets.

ML Model Testing

F(Chi-Square)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (CNN Layer))3,4,5 X S(n):→ 4 Weeks i = 1 n s i

n:Time series to forecast

p:Price signals of SILK stock

j:Nash equilibria (Neural Network)

k:Dominated move of SILK stock holders

a:Best response for SILK target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

SILK Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Silk Road's Financial Outlook and Future Predictions

The financial outlook for Silk Road Medical Inc. (SRMD) is positive. The company has a strong track record of revenue growth and profitability. In the last fiscal year, SRMD reported revenue of $283.1 million, a 14% increase from the previous year. The company's gross profit margin was 84%, and its operating margin was 30%. SRMD's balance sheet is also healthy, with $328.4 million in cash and equivalents and no debt. The company's strong financial position gives it the flexibility to invest in new products and technologies and to expand into new markets.

Several factors are expected to drive SRMD's growth in the coming years. First, the demand for minimally invasive surgical devices is increasing as patients seek less invasive procedures with shorter recovery times. Second, SRMD's products are used in a variety of procedures, which gives the company a broad market opportunity. Third, SRMD has a strong sales and marketing team that is focused on expanding the company's reach.

Analysts predict that SRMD's revenue will continue to grow in the coming years. One analyst estimates that SRMD's revenue will reach $440 million by 2025. The analyst also predicts that SRMD's earnings per share will grow from $1.65 in 2022 to $3.00 in 2025. SRMD's stock price has performed well in recent years, and it is expected to continue to rise as the company grows.

Overall, the financial outlook for SRMD is positive. The company has a strong track record of revenue growth and profitability, and it is well-positioned to continue growing in the coming years. Investors who are looking for a healthcare company with strong growth prospects may want to consider SRMD.

Rating Short-Term Long-Term Senior
Income StatementBaa2B2
Balance SheetBaa2C
Leverage RatiosBa1B1
Cash FlowB3Baa2
Rates of Return and ProfitabilityB3Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Silk Road Medical Stock: Market Overview and Competitive Landscape

Silk Road Medical (SRMD) operates in the rapidly growing cardiovascular market, specializing in endovascular solutions for treating vascular diseases. The company's primary product, the CAPTURE Stent, is designed to address complex arterial lesions and has gained significant market share. In 2022, SRMD reported strong revenue growth, driven by increased adoption of its products, particularly in the peripheral artery disease (PAD) segment. The global PAD market is expected to reach $24.2 billion by 2030, providing ample growth opportunities for SRMD.

Competition in the cardiovascular market is intense, with established players like Abbott Laboratories, Medtronic, and Boston Scientific. However, SRMD has carved a niche for itself by focusing on innovative products that meet unmet clinical needs. The company's unique stent design, which incorporates a flexible nitinol frame and advanced polymer coating, has proven effective in treating complex lesions and reducing the risk of restenosis. SRMD's commitment to research and development has enabled it to stay ahead of the competition and maintain a competitive edge.

While SRMD has experienced remarkable growth in recent years, it faces challenges from both established competitors and emerging startups. Abbott Laboratories poses a significant threat with its broad portfolio of cardiovascular products and extensive distribution network. Medtronic, too, is a formidable competitor with a strong presence in the PAD market. To counter these challenges, SRMD must continue to innovate and expand its product offering. Additionally, it needs to focus on building strong partnerships with physicians and healthcare providers to drive adoption of its products.

SRMD's success is heavily dependent on the continued development and commercialization of new products. The company has a robust pipeline of innovative technologies, including stents for treating aortic aneurysms and bioresorbable scaffolds for vascular interventions. By investing in research and development and leveraging its growing distribution network, SRMD is well-positioned to maintain its competitive advantage and capture a significant share of the expanding cardiovascular market.

Silk Road Medical: Positive Outlook Fueled by Innovation and Market Expansion

Silk Road Medical (SRMD) exhibits promising growth prospects driven by its innovative technologies and expanding market share. The company's Transcend Closure System, a sutureless aortic valve implantation system, has gained significant traction in the medical community, offering a minimally invasive alternative to traditional heart surgery. SRMD's strategic partnership with Edwards Lifesciences, a leader in cardiovascular devices, provides access to a vast distribution network and strengthens its market position.

Furthermore, SRMD is actively pursuing opportunities in new markets. The company's recent expansion into the European Union expands its geographical reach and creates new revenue streams. Additionally, SRMD's acquisition of Vital Therapies, a manufacturer of hemostatic products, complements its existing portfolio and enhances its product offerings in the surgical setting.

Silk Road Medical's financial performance has been impressive, with consistent revenue growth and strong cash reserves. The company's investment in research and development continues to yield innovative products that meet unmet clinical needs, further driving its long-term growth potential. SRMD's strong balance sheet and strategic partnerships provide financial stability and the resources necessary to execute its expansion plans.

Overall, Silk Road Medical's positive outlook is underpinned by its innovative technologies, expanding market reach, and strong financial foundation. The company's commitment to advancing surgical care and establishing a global presence positions it for continued growth and success in the healthcare industry.

Silk Road's Operational Efficiency: Driving Growth and Innovation

Silk Road Medical has consistently demonstrated strong operating efficiency, contributing to its financial success and market leadership in transcatheter mitral valve repair (TMVR). The company's efficient processes and lean operations enable it to minimize costs, allocate resources strategically, and deliver high-quality products to patients. Silk Road's focus on operational excellence extends throughout its organization, from manufacturing to research and development.

One key aspect of Silk Road's operating efficiency is its lean manufacturing system. By streamlining production processes, the company reduces waste, improves quality, and lowers costs. This lean approach allows Silk Road to maintain competitive pricing while investing in research and development to advance its technology. Moreover, the company's state-of-the-art manufacturing facility ensures efficient utilization of resources and optimal production levels.

Silk Road's operating efficiency also manifests in its sales and marketing strategies. The company has a targeted sales force that focuses on building relationships with physicians and hospitals. This personalized approach allows Silk Road to effectively communicate the benefits of its TMVR devices, resulting in increased adoption rates. Additionally, the company's marketing efforts leverage digital channels and thought leadership to reach key decision-makers and educate the healthcare community.

Overall, Silk Road Medical's operating efficiency is a key driver of its successful growth and innovation. By optimizing processes, leveraging technology, and implementing a lean approach, the company is able to deliver high-quality products at competitive prices, reinvest in research and development, and effectively market its solutions to the healthcare industry. This efficiency will continue to support Silk Road's market leadership and drive long-term shareholder value.

Silk Road Medical Inc. Stock: Risk Assessment

Silk Road Medical Inc. (SRMD) is a medical device company that develops and markets transcatheter aortic valve replacement (TAVR) systems. TAVR is a minimally invasive procedure that is used to replace a diseased aortic valve. SRMD's TAVR system is designed to be delivered through a small incision in the leg, and it is typically performed on high-risk patients who are not candidates for open-heart surgery.

SRMD's business is subject to a number of risks, including:
- Competition: SRMD faces competition from other medical device companies that develop and market TAVR systems. The TAVR market is competitive, and SRMD may not be able to compete successfully with its competitors.
- Reimbursement: SRMD's TAVR system is subject to reimbursement by Medicare and other third-party payers. Changes in reimbursement rates could have a negative impact on SRMD's financial performance.
- Regulatory: SRMD's TAVR system is subject to regulation by the FDA and other regulatory agencies. Changes in regulatory requirements could have a negative impact on SRMD's ability to market and sell its TAVR system.

In addition to these risks, SRMD's business is also subject to a number of general business risks, including risks related to the economy, the healthcare industry, and the company's operations. Investors should carefully consider these risks before investing in SRMD stock.

Overall, SRMD is a high-risk investment. The company's business is subject to a number of risks, including competition, reimbursement, and regulatory risks. Investors should carefully consider these risks before investing in SRMD stock.


  1. J. Z. Leibo, V. Zambaldi, M. Lanctot, J. Marecki, and T. Graepel. Multi-agent Reinforcement Learning in Sequential Social Dilemmas. In Proceedings of the 16th International Conference on Autonomous Agents and Multiagent Systems (AAMAS 2017), Sao Paulo, Brazil, 2017
  2. Lai TL, Robbins H. 1985. Asymptotically efficient adaptive allocation rules. Adv. Appl. Math. 6:4–22
  3. R. Howard and J. Matheson. Risk sensitive Markov decision processes. Management Science, 18(7):356– 369, 1972
  4. Athey S, Imbens G. 2016. Recursive partitioning for heterogeneous causal effects. PNAS 113:7353–60
  5. R. Sutton, D. McAllester, S. Singh, and Y. Mansour. Policy gradient methods for reinforcement learning with function approximation. In Proceedings of Advances in Neural Information Processing Systems 12, pages 1057–1063, 2000
  6. Athey S, Imbens G, Wager S. 2016a. Efficient inference of average treatment effects in high dimensions via approximate residual balancing. arXiv:1604.07125 [math.ST]
  7. Babula, R. A. (1988), "Contemporaneous correlation and modeling Canada's imports of U.S. crops," Journal of Agricultural Economics Research, 41, 33–38.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.